Mochida Pharmaceutical Co.,Ltd.(4534) News

Announcement of Partnership Agreement for the Biosimilar of Follitropin Alfa

[Summary] Notice Concerning Determination of Offering Price and Other Matters

Launch of “Avarept Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition

Announcement of a Partnership Agreement for Dinagest in South Korea and Thailand

Notice Regarding the Succession of Manufacturing and Marketing Approval and Asset Acquisition of URECE Tablets

Notice Regarding Resolution on Share Repurchase

[Summary] Notice Regarding Secondary Offering of Shares

Consolidated Financial Results for the Nine Months Ended December 31, 2025(Under Japanese GAAP)(Completion of Interim Review by an Independent Auditor

Announcement of Manufacturing and Marketing Approval for Tocilizumab BS MA in Japan

[Summary] Consolidated Financial Results for the Nine Months Ended December 31, 2025

Notice Concerning Revisions to Full-Year Consolidated Financial Results Forecasts

Announcement of the Establishment of Mochida Medical USA, Inc.

Obtained manufacturing and marketing approval in Japan for Avarept Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient

Driven by a common vision, Mochida Pharmaceutical Co., Ltd. and Duchesnay Inc. sign a partnership to help address the issue of drug gap in Japan

[Summary] Consolidated Financial Results for the Six Months Ended September 30, 2025

Notice Concerning Subscription to a Third-Party Allotment of Shares and the Acquisition of Shares of And Pharma Co., Ltd.

[Summary] Consolidated Financial Results for the Three Months Ended June 30, 2025

Notice Regarding Approval of the Continuation of the Policy on Large-Scale Share Acquisition and Changes of Special Committee Member

Continuation of the Policy on Large-Scale Share Acquisition(Takeover Response Policy)

The Mochida Pharmaceutical Group’s“25-27 Medium-term Management Plan” Notice